Management of Dermatologic Toxicities
May 2015
in “
Journal of the National Comprehensive Cancer Network
”
TLDR Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.
In 2015, Dr. Mario E. Lacouture highlighted the significance of early management of dermatologic toxicities, which affect the skin, hair, nails, and mucous membranes, in cancer treatment due to their impact on patients' quality of life and potential to alter treatment. Different cancer therapies were noted to cause various skin rashes, with EGFR inhibitors causing an acneiform rash in most patients, dMEK inhibitors in over 50% of patients, and BRAF inhibitors causing a quickly spreading maculopapular rash. Prophylactic antibiotics were effective in preventing rashes from EGFR inhibitors. Alopecia, a concerning side effect, could occur with inhibitors of BRAF, MEK, EGFR, and hedgehog signaling pathway. Management strategies for alopecia included correcting thyroid, iron, and vitamin abnormalities, and using minoxidil 5% twice daily. Scalp cooling during chemotherapy was found to prevent hair loss in a study of 1400 patients.